Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022

The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%.

Thomas Jarratt, Associate Analyst for GBI Research, explains: “Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi’s Praluent (alirocumab) is expected to help mitigate losses associated with falling revenues of its key products Lovenox (enoxaparin) and Plavix (clopidogrel).

“Novartis’ heart failure drug Entresto was introduced to market in July 2015, and GBI Research expects its revenues to increase dramatically during the forecast period. Entresto is a combination drug which has shown efficacy shown in clinical trials. Coupled with a high cost, which amounts to over $4,500 annually per patient, the drug contributes to a very high revenue forecast of $5.7 billion by 2022.”

The sheer number of expirations and approvals means the structure of the market will shift significantly. Current market leader AstraZeneca is set to mitigate the damage associated with the introduction of generic Crestor through the rising revenues attributed to its antiplatelet drug Brilinta.

Jarratt continues: “the market shares of Sanofi and Novartis are expected to increase strongly over the forecast period, leading to Sanofi becoming market leader, and both brands achieving revenues in excess of $7 billion by 2022.”

To request free report preview e-mail to - gdreports@globaldata.com?subject=Sample%20Pages%20for%20GBIHC414MR-%20Global%20Cardiovascular%20Disease%20Market%20to%202022(

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

John Carpenter House, John Carpenter Street, London EC4Y 0AN, UK.

This release was published on openPR.